CL001_559
22 Nov 2021
CL001_559
ACTRN12621001342808
A Phase 1 First In Human, Multicenter, Open label Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In Subjects With Solid Tumors
–
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I, Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2021-08-02 |
Anticipated End Date | 2022-04-22 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Gonzalo Tapia Rico |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs